MK-2206 2HCl 化学構造
分子量: 480.39

品質と確認

製品表彰状(156)

カスタマーレビュー(16)

Quality Control & MSDS

製品情報

  • Compare Akt Inhibitors
    Akt阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 MK-2206 2HClは高度選択的に Akt1, Akt2 and Akt3を抑制して、 IC50がそれぞれ 8 nM, 12 nM と 65 nMになる。
目標 Akt1 Akt2 Akt3
IC50 8 nM 12 nM 65 nM [1]
In vitro試験 MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
NCI-H292 M2jWRmN6fG:2b4jpZ{BCe3OjeR?= NE\XXJE{KM7:TR?= Ml3aO|IhcA>? MYfEUXNQ NH7IcFFKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=
A431 MWfLbY5ie2ViQYPzZZk> MWO1JO69VQ>? M3nFSVUhcA>? Mn3oSG1UVw>? Ml64V5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs
HepG2 MlfUR5l1d3SxeHnjJGF{e2G7 MUWxNEDPxE1? MWiyOEBp NIHCSXZFVVOR MX7T[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK=
Sk-Hep1 M2rXTGN6fG:2b4jpZ{BCe3OjeR?= MXSxNEDPxE1? NFjabI4zPCCq M{mz[mROW09? NIT3c4lU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI>
OCUT1 cells harbored PIK3CA (H1047R+/+) MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LB[|Mh|ryP MY[1JIQ> NU\TVmR[TE2VTx?= M4W0VGlEPTB;MD6xOEDPxE1?
K1 cells harbored PIK3CA (E542K+/+) MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHXWG1yOyEQvF2= NGn5V2s2KGR? NFm1SJhFVVOR NULX[4xIUUN3ME2wMlUzKM7:TR?=
FTC133 cells harbored PTEN (allele deletion and R130+) NH\US4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPtN{DPxE1? NVTYcFVkPSCm M3Xzd2ROW09? NWLSNJdoUUN3ME2wMlE5KM7:TR?=
C643 cells harbored HRAS (G13R+/−) M3TDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOzJO69VQ>? NHTrUpU2KGR? NYjyWGhlTE2VTx?= M3zES2lEPTB;MD6yO{DPxE1?
Hth7 cells harbored NRAS (Q61R+/−) NGLYUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYPHE{KM7:TR?= MlS0OUBl NWLWW5d5TE2VTx?= M4nzVmlEPTB;ND61JO69VQ>?
TPC1 cells harbored RET/PTC1 rearrangement NWPhfFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;1N{DPxE1? MXG1JIQ> MlvRSG1UVw>? MkDCTWM2OD1yLkW5JO69VQ>?
Hth74 M3nRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f4NFMh|ryP MoHuOUBl M3Tvc2ROW09? Mk\GTWM2OD1{LkG5JO69VQ>?
KAT18 NHTwbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D2TlMh|ryP NHP0UoE2KGR? M4LDSmROW09? NWjVUWxXUUN3ME20MlYzKM7:TR?=
SW1736 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexNFAh|ryP MUe1JIQ> M1q4PWROW09? NEDNZpJKSzVyPUS3MlU3KM7:TR?=
WRO M3PkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxNFAxKM7:TR?= MXW1JIQ> NV;SZZUxTE2VTx?= M4rkWWlEPTB-MUCwNEDPxE1?
TAD2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjWUlNvOTByMDFOwG0> NVLERYl3PSCm M3jIfmROW09? MUHJR|UxRjFyMECg{txO
LN229 M1\zbGFxd3C2b4Ppd{BCe3OjeR?= NV\GT5RVOC53IN88US=> NX7DSYtCPjBiaB?= NFPwb2VFVVOR MV;BeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>?
T98G M2LTZmFxd3C2b4Ppd{BCe3OjeR?= M3H0e|AvPSEQvF2= MnrwOlAhcA>? M1u5ZmROW09? MnOwRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ?
HC11 NVXieGR4TnWwY4Tpc44hSXO|YYm= NGriO4gyOCEQvF2= NHX1UWIzPCCq MWjEUXNQ MWXJcohq[mm2czFOtk1k[XOnaX6gZY5lKEGGUmCgd5lvfGinc3nz
MOLT-4 MYjDfZRwfG:6aXOgRZN{[Xl? MXqxNEDPxE1? M3;0OFQ5KGh? MVPEUXNQ NHW1dGRKSzVyPUGuO-KBkc7:TR?=
CEM-R NGXa[2REgXSxdH;4bYMhSXO|YYm= M2LkcVExKM7:TR?= NVe4b3hjPDhiaB?= MmT6SG1UVw>? MWLJR|UxRTNwM,MAje69VQ>?
CEM-S MoD2R5l1d3SxeHnjJGF{e2G7 MnLGNVAh|ryP M1[wXlQ5KGh? MYjEUXNQ NY\0NlhyUUN3ME21MlHjiIoQvF2=
MOLT-4 Moj3SpVv[3Srb36gRZN{[Xl? M2\YS|ExKM7:TR?= NI[2NW4zPCCq Mo\PSG1UVw>? NWf2eGM1SmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?=
MOLT-4 NXHSd2NGTnWwY4Tpc44hSXO|YYm= NI\RcIY16oDLzszN M2XuR|QhcA>? MWTEUXNQ NFHTS3VKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ?
CEM-R MX3GeY5kfGmxbjDBd5NigQ>? NUfQWZRnPOLCid88US=> NGX2[m81KGh? MXzEUXNQ NVfWTJlFUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{
CEM-S M4D0UGZ2dmO2aX;uJGF{e2G7 NH;xcWs16oDLzszN MmX3OEBp NE\JSHNFVVOR NUfJT48xUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{
HepG2 cell NULzUWxvU2mwYYPlJGF{e2G7 NVPyNWxYOjBizszN MVWyOEBp MmHLSG1UVw>? M4rGZmRwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?
HepG2 cell M3;OPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLDN|Ah|ryP M1exRlI1KGh? NX7vVFhpTE2VTx?= NVXjW5BpUW6qaXLpeJMh[2WubDDndo94fGh?
HepG2 cell NV;TVopRSXCxcITvd4l{KEG|c3H5 M17HflIxKM7:TR?= MoLmNlQhcA>? NV3KVnBVTE2VTx?= MnnlTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?
GEO MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz2emE2ODBibl2= NXXUSpQ4PzJiaB?= M1H3d2ROW09? MUXJcohq[mm2czDj[YxtKGe{b4f0bC=>
CNE-1 M{DISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNEDPxE1? NUnMZ4toQTZiaB?= M{HrNmROW09? M{fyW2lEPTB;Mj65OkDPxE1?
CNE-2 NE\aUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7GNVAh|ryP MnHJPVYhcA>? M33FUmROW09? NInBfopKSzVyPUSuOVMh|ryP
HONE-1 NGTHS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxNEDPxE1? MXm5OkBp NWS5OHpCTE2VTx?= NWTJemp[UUN3ME2zMlM4KM7:TR?=
SUNE-1 M{fnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPSNVAh|ryP MlrwPVYhcA>? MXrEUXNQ NHvEeoRKSzVyPUCuOVIh|ryP
CNE-2 MWfGeY5kfGmxbjDBd5NigQ>? MVOxNEDPxE1? NFfpeIQ1QCCq NW\MVnBETE2VTx?= NH:1T4xKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz
HONE-1 M1vvfGZ2dmO2aX;uJGF{e2G7 MXKxNEDPxE1? NGTIfVA1QCCq MkfVSG1UVw>? M3\YZmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF?
NEC8 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7PTWM2OD1yLkC5OlUyKM7:TR?=
P12-ICHIKAWA NYjhcXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rre2lEPTB;MD6xNVYzKM7:TR?=
MDA-MB-175-VII NEO2VYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMUO3N|gh|ryP
AsPC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[3Noc6UUN3ME2wMlIzOTJ{IN88US=>
T47D NHWwV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr1T5F{UUN3ME2wMlI5OjVizszN
HH MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\2NHh1UUN3ME2wMlMxOjh|IN88US=>
MOLT-16 NG\HeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwM{CzNkDPxE1?
ES5 NELselJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofHTWM2OD1yLkO0OFU2KM7:TR?=
RS4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[xd2lKSzVyPUCuN|Q3OSEQvF2=
KARPAS-45 NVrp[oVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHyWJc{UUN3ME2wMlM4OzJzIN88US=>
NCI-H720 NVL1R41nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXBNpo6UUN3ME2wMlM4Pjd7IN88US=>
H9 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[3XGlEPTB;MD6zPFg5OyEQvF2=
EFM-19 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Xd4tKSzVyPUCuOFQxOSEQvF2=
SBC-1 NXTkNYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILwflNKSzVyPUCuOFQxOzVizszN
A4-Fuk MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fmN2lEPTB;MD60Olg3QCEQvF2=
NCI-H1563 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInqWFhKSzVyPUCuOFgyQDlizszN
HCC1419 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37MZWlEPTB;MD60PFg6OiEQvF2=
H-EMC-SS M13vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfFdmxPUUN3ME2wMlQ6QTN7IN88US=>
BHT-101 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYeyVHFvUUN3ME2wMlUzQTZzIN88US=>
IGROV-1 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfhVGtKSzVyPUCuOVUzPDlizszN
HGC-27 NFr6dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNU[3PFMh|ryP
MDA-MB-361 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwNUe3OlEh|ryP
KE-37 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL5OIpKSzVyPUCuOVgzPiEQvF2=
HCC70 M3zadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKzNXBQUUN3ME2wMlU6QDJ5IN88US=>
LNCaP-Clone-FGC NXn4Nox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHVPZVKSzVyPUCuOlExPDhizszN
HAL-01 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNkKxN{DPxE1?
HT MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzuVIVKSzVyPUCuOlMzOzlizszN
MDA-MB-415 NEXNWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNkO2NlYh|ryP
NOS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnZNWJVUUN3ME2wMlY{PzJ|IN88US=>
DU-145 NWrpbWJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fsUmlEPTB;MD62OFc1PSEQvF2=
OCUB-M MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\uTWM2OD1yLkewPVY3KM7:TR?=
VA-ES-BJ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPtOm5KSzVyPUCuO|MxOjVizszN
J-RT3-T3-5 NH3q[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTVTWM2OD1yLke0OFA{KM7:TR?=
MOLT-4 M{XuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K1OWlEPTB;MD64NFU5OiEQvF2=
NB7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm1TWM2OD1yLkiyOFEyKM7:TR?=
L-363 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOwTWM2OD1yLkizOFQzKM7:TR?=
NKM-1 M1L6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTwTJY4UUN3ME2wMlg3OjV|IN88US=>
HOP-92 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwOEeyNlMh|ryP
OAW-42 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXxU5hiUUN3ME2wMlg5PzJizszN
HuO9 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPRdmlKSzVyPUCuPVI4PTFizszN
MFE-280 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2T2lEPTB;MD65OlQ3PSEQvF2=
EM-2 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPrPWlKSzVyPUCuPVc6OzlizszN
NCI-H520 NIWxU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwOUi1PVIh|ryP
LB2241-RCC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1yLkm5O|M1KM7:TR?=
SK-NEP-1 M3vPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLD[ZJCUUN3ME2xMlE1PDh3IN88US=>
LXF-289 NEeyUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiwSXNvUUN3ME2xMlE4OTV4IN88US=>
EPLC-272H MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqwTWM2OD1zLkG3NlU3KM7:TR?=
COLO-684 NEC0XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LzWmlEPTB;MT6yN|czPSEQvF2=
ES1 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC3TWM2OD1zLkK0NFY2KM7:TR?=
DOHH-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOwTWM2OD1zLkK4NlA{KM7:TR?=
CTB-1 NHHnb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\yNI1KSzVyPUGuNlg6QSEQvF2=
G-401 M{LSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\1TWM2OD1zLkK5O|k2KM7:TR?=
LoVo NHTCN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwM{K1N|Qh|ryP
Ramos-2G6-4C10 NGPSSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG2NYRKSzVyPUGuN|M4ODFizszN
MFM-223 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwM{S0OlEh|ryP
PA-1 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTZU5VUUUN3ME2xMlM2OjZ3IN88US=>
697 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL4WohKSzVyPUGuN|c3OTZizszN
QIMR-WIL NGfMSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnae4pKSzVyPUGuOFkyOTZizszN
HOS M{nvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjtZ2FnUUN3ME2xMlQ6PTV6IN88US=>
DMS-273 NUG2SlhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnaUJdvUUN3ME2xMlUyQTV7IN88US=>
ME-180 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT5do5KSzVyPUGuOVY5QTFizszN
HCC2218 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHZTWM2OD1zLk[4NlI2KM7:TR?=
CAL-54 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TFeGlEPTB;MT63NVI1OiEQvF2=
OMC-1 M2S3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjWXIxOUUN3ME2xMlc1Pjd5IN88US=>
COR-L105 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTOXVVKSzVyPUGuO|k4OzdizszN
BV-173 NXPtfYFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfyTWM2OD1zLkixNFc1KM7:TR?=
RKO NVvqUIRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnpOJZKUUN3ME2xMlg4OTBzIN88US=>
SNU-387 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwOEi0NFYh|ryP
SW1088 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Pm[mlEPTB;MT65OFYxPiEQvF2=
Hs-578-T MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;lZVJKSzVyPUKuNVE1OzNizszN
OC-314 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJwMUWwPFYh|ryP
RMG-I M2TzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHtZ5ZKSzVyPUKuNVY{QThizszN
NCI-H1395 M2\CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJwMUiwPVEh|ryP
GAMG MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qyXmlEPTB;Mj6yN|g1PSEQvF2=
LB1047-RCC NEXq[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzSOVlQUUN3ME2yMlI1OzF5IN88US=>
MN-60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLFTWM2OD1{LkK5PVI{KM7:TR?=
OAW-28 NIHHNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ewc2lEPTB;Mj6yPVk2OSEQvF2=
NCI-H2228 NHPPc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrNWxKSzVyPUKuN|E2PTJizszN
ABC-1 NWHjbmF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XmTWlEPTB;Mj6zN|I2OyEQvF2=
LS-513 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLtPYE{UUN3ME2yMlM{PDh2IN88US=>
KS-1 NHXwOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfrOIdKSzVyPUKuN|gyQTFizszN
NB69 NWWwUG1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H2bWlEPTB;Mj6zPFk5OyEQvF2=
VM-CUB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojETWM2OD1{LkO5NFg{KM7:TR?=
D-423MG MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDHTWM2OD1{LkSxNFQ1KM7:TR?=
EW-18 NWrOPIdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LJXGlEPTB;Mj60NVk{QSEQvF2=
YH-13 NYDa[5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\YTWM2OD1{LkS2NVU{KM7:TR?=
T-24 M4i4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrhW4U1UUN3ME2yMlQ4QDhzIN88US=>
ES8 M2q5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwNEmyPFch|ryP
ES3 NH3mWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfHTWM2OD1{LkS5O|U6KM7:TR?=
RXF393 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPvfGVsUUN3ME2yMlYxPDh5IN88US=>
RPMI-8226 M1rHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLqZYFKSzVyPUKuOlI6PTNizszN
AGS NVL0WYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXxTWM2OD1{LkeyNVM4KM7:TR?=
HCC1395 NHfSVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\sT5dJUUN3ME2yMlc2OTh5IN88US=>
MV-4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOxWHV1UUN3ME2yMlc2OjZ4IN88US=>
A204 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;DTWM2OD1{LkizPFczKM7:TR?=
MCF7 NH:zbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LDZ2lEPTB;Mj64OlEyPyEQvF2=
SNU-423 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\GS2lEPTB;Mj64PVI1OiEQvF2=
NCI-H1048 NEe2cXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfibpM{UUN3ME2yMlk3QDZ3IN88US=>
GR-ST NEDUWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGxTWM2OD1|LkC0OlEyKM7:TR?=
EoL-1- NULyRoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTmTHlKSzVyPUOuNFcxPThizszN
HuH-7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Hb2lEPTB;Mz6wPVQ3PCEQvF2=
OS-RC-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwMUGxPUDPxE1?
EW-3 NGm1SHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwMUm1Nlkh|ryP
NCI-H747 NVLjbpVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrrUlBGUUN3ME2zMlIxPjl2IN88US=>
EW-16 NH\k[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H1NGlEPTB;Mz6yNVg4QSEQvF2=
DOK MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm5fY1KSzVyPUOuNlI5PTlizszN
HCC2157 NW\RW2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwM{ixO|kh|ryP
OVCAR-3 NYnYd|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnXTWM2OD1|LkSwO|g3KM7:TR?=
NCI-H1623 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNwNEGyNlQh|ryP
H4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNwNEW2NlYh|ryP
SW1710 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzvbYpiUUN3ME2zMlQ3Pjd6IN88US=>
RT-112 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu0SpJrUUN3ME2zMlUzOzh6IN88US=>
DMS-114 NH76W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjoSFFMUUN3ME2zMlYzOjd6IN88US=>
AN3-CA MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vyXGlEPTB;Mz62NlQ2PiEQvF2=
KNS-62 NFPsem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwNkOzN|gh|ryP
SJRH30 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi5TVdKSzVyPUOuOlkyOjJizszN
G-402 NHTGeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXudZRKUUN3ME2zMlcxPzFzIN88US=>
MHH-PREB-1 NUPJVZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNwN{KwN|gh|ryP
P30-OHK NHLyZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3QO2VKSzVyPUOuPFA6PzZizszN
RVH-421 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LE[2lEPTB;Mz64NVc5QCEQvF2=
LU-134-A M4XXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i1SGlEPTB;Mz64PFQzQCEQvF2=
ECC10 NYDRdoQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe0Z2tMUUN3ME2zMlk{PjJ{IN88US=>
TGW M4mydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTRwMEKzNFUh|ryP
MLMA NHHub5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHJbVZKSzVyPUSuNFI6PjZizszN
SCC-25 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWycHBKSzVyPUSuNFY2PjZizszN
TYK-nu M{Xue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzQTWM2OD12LkC5OVM1KM7:TR?=
LAMA-84 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC4TWM2OD12LkG0NVkyKM7:TR?=
Calu-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwMkS0NVYh|ryP
NCI-H460 M3z6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn1[YhKSzVyPUSuNlY1PDNizszN
EGI-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvLNmxKSzVyPUSuN|c4PzhizszN
NCI-H292 NEO0fXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRwM{ixOFYh|ryP
HCE-T Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rPZWlEPTB;ND60NVU4QSEQvF2=
EW-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;pPIlKSzVyPUSuOFE5OzhizszN
ATN-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHzU3VKSzVyPUSuOFQ{ODRizszN
NB5 NWjwSWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD12LkWzOlk4KM7:TR?=
KLE M13PXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvkVY9KUUN3ME20MlcxOTl6IN88US=>
CAL-39 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjRZ2xOUUN3ME20MlczOTR4IN88US=>
TI-73 NH7rUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwOEC2NFkh|ryP
HO-1-N-1 M3Hycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfIV3dKSzVyPUSuPVQzKM7:TR?=
786-0 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK3UW5KSzVyPUSuPVQ3PzNizszN
SK-N-DZ NU\QdoZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLjRoE5UUN3ME20Mlk3OTR{IN88US=>
NCI-H446 NV7hfpJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPzXGZKSzVyPUWuNlAxODlizszN
ETK-1 NVu0Z5lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jkdmlEPTB;NT6yNVE3PSEQvF2=
BT-20 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwMkGzOVMh|ryP
MEL-HO MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfvcW51UUN3ME21MlM4OzN4IN88US=>
CAL-27 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrzb3UzUUN3ME21MlQ3OzN7IN88US=>
SW872 M33mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3YTmRtUUN3ME21MlU6PDJ6IN88US=>
RPMI-2650 NHjEUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTVwNk[xPVkh|ryP
PFSK-1 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmwXHY4UUN3ME21MlczPzN{IN88US=>
SF295 M2DVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3PWlEPTB;NT64NFY{OyEQvF2=
Becker MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTVwOE[0O|Ih|ryP
Saos-2 NVLYSmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXuTWM2OD13Lki2OVMh|ryP
SK-OV-3 M1LIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XTPGlEPTB;NT65PVgyPiEQvF2=
VMRC-RCZ NEPUTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLUTWM2OD14LkC4O|c{KM7:TR?=
EW-22 M1P4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTZwMUm2OFkh|ryP
BT-474 MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTZwMkOzJO69VQ>?
BFTC-909 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorLTWM2OD14LkOwN|Q2KM7:TR?=
NB12 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7pRo9KSzVyPU[uN|kxPzFizszN
D-263MG MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[zTWM2OD14LkS1NVY6KM7:TR?=
SNB75 NVKxWnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjCV2F5UUN3ME22MlYxOTR|IN88US=>
A704 NVO0SlU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuxb5RKSzVyPU[uOlMxPiEQvF2=
NCI-H1693 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPu[I1uUUN3ME22MlY{PjB2IN88US=>
LN-405 NWXZOJF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPFV5c4UUN3ME22Mlc6Pjd{IN88US=>
CHL-1 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxcoZQUUN3ME22MlgxODd7IN88US=>
A498 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H4dWlEPTB;Nj64NVk3OSEQvF2=
TE-12 NFO4Z2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTZwOEO4NVch|ryP
TE-6 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq0R2ZKSzVyPU[uPVMxOzhizszN
AU565 NVz3UVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTZwOU[5OVch|ryP
RD M161bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXOZ4hKSzVyPU[uPVgzQDRizszN
SW1463 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXZRmNEUUN3ME23MlEyOTZ6IN88US=>
LU-99A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTdwMUSzNlIh|ryP
NCI-H28 M2S5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXBTWM2OD15LkK5NlQh|ryP
MC-IXC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTYTWM2OD15LkS4OVc3KM7:TR?=
GP5d M3PHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f6SGlEPTB;Nz60PFc3PCEQvF2=
GB-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTVbJJKSzVyPUeuOVQ5ODRizszN
CAL-33 M1;jSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTdwNk[yN|Mh|ryP
MSTO-211H M4PlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X1ZmlEPTB;Nz62O|M{PiEQvF2=
TE-5 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjLbG1kUUN3ME23Mlc6OzN2IN88US=>
D-566MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e5[GlEPTB;OD6wOFQzQSEQvF2=
JVM-3 Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPyV2dUUUN3ME24MlE2OjZ6IN88US=>
T98G NXPyOVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv1TWM2OD16LkG4NFY4KM7:TR?=
HCC1954 NETu[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDQSo9KSzVyPUiuOFUyODRizszN
SF126 NULEWXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXHcIs1UUN3ME24MlQ2QTN4IN88US=>
LB996-RCC NHS1XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rWbGlEPTB;OD61N|I2PyEQvF2=
SKG-IIIa NGnFW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\YTWM2OD16Lk[zNFY6KM7:TR?=
NCI-SNU-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv2bI5NUUN3ME24MlY1PjR|IN88US=>
LB771-HNC M{fSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{eyfWlEPTB;OD62OFY6PiEQvF2=
SCC-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfyTWM2OD16Lk[4NlE6KM7:TR?=
CAMA-1 M4Xa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrWOYZvUUN3ME24Mlc4OTR4IN88US=>
D-502MG NYfCS5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[5S24{UUN3ME24Mlc5PjJ7IN88US=>
ESS-1 M2XjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fUUmlEPTB;OD64PFcxPCEQvF2=
HEC-1 M{LxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPneopKSzVyPUiuPFk5PjZizszN
NB10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TUV2lEPTB;OT6wNlIzPCEQvF2=
8505C MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWryPHdKUUN3ME25MlA1OjN{IN88US=>
EFO-27 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWwTWM2OD17LkG2OFEzKM7:TR?=
HN NYrLV|AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DqVGlEPTB;OT6xOlYzQCEQvF2=
DSH1 NWXYfY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDr[mlKSzVyPUmuNlA5PyEQvF2=
NBsusSR NWDx[Gs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D5OGlEPTB;OT6yO|QxOiEQvF2=
LS-123 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHiTWM2OD17LkOxO|YyKM7:TR?=
SHP-77 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XTdWlEPTB;OT6zPVk{PSEQvF2=
ACN M1fZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\TfWhKSzVyPUmuOVMzPzdizszN
U251 NIKyRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPJOHRKSzVyPUmuOlU2PDRizszN
A431 NXXibZh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO4TWM2OD17LkiwNlM5KM7:TR?=
5637 NUjWPHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG4N45QUUN3ME25Mlg1QTh2IN88US=>
MDA-MB-157 NFvpV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDaTWM2OD17LkmyPFc5KM7:TR?=
A101D M1y0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPiTWM2OD17Lkm5PVc1KM7:TR?=
YKG-1 M{O5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu2PY5OUUN3ME2xNE4zODB4IN88US=>
LAN-6 M{DjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFyLkKxOlQh|ryP
OVCAR-5 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;WTWM2OD1zMD6yOFM{KM7:TR?=
A549 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nqXGlEPTB;MUCuN|k4OyEQvF2=
no-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TCd2lEPTB;MUCuOFM2OyEQvF2=
SF539 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFyLkmwOFEh|ryP
A388 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGyUllvUUN3ME2xNU4{QDl5IN88US=>
DEL NWLIUnV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;3fXJKSzVyPUGxMlQzPCEQvF2=
SW954 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rXd2lEPTB;MUGuOFY3QCEQvF2=
TK10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFzLkWyO|Eh|ryP
SW756 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ZSmlEPTB;MUGuOVI6PCEQvF2=
PC-3 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFzLkW3OlQh|ryP
ONS-76 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFzLk[zOkDPxE1?
A427 NV7PeYNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXiU|FKSzVyPUGxMlcxQTNizszN
MEG-01 NVHNS2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fWUmlEPTB;MUGuO|UxQSEQvF2=
BB30-HNC NWPqOpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV2xcHdkUUN3ME2xNU44QTh{IN88US=>
NCI-H1299 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nkPGlEPTB;MUGuPFA6OyEQvF2=
GCT M4ewdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEntcFJKSzVyPUGxMlgzOjhizszN
D-247MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HYNmlEPTB;MUGuPVY3OyEQvF2=
CFPAC-1 NVzRe4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHwTWM2OD1zMT65O|gzKM7:TR?=
EKVX MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrqRlFKSzVyPUGyMlA{OTNizszN
CAL-51 M2C4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ETWM2OD1zMj6wO|E3KM7:TR?=
BB49-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD1zMj6xNVc4KM7:TR?=
RPMI-7951 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULISnpoUUN3ME2xNk4yQDV2IN88US=>
RH-1 NGLwW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXTbIVKSzVyPUGyMlIyQDRizszN
BCPAP NUDqNWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnrTWM2OD1zMj60O|Q6KM7:TR?=
GCIY NYnnZ3kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nPWGlEPTB;MUKuOVIxQSEQvF2=
KNS-81-FD NVG1N2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGwN4xKSzVyPUGyMlU5PjlizszN
KYSE-140 M1fTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXOTWM2OD1zMj64OVk2KM7:TR?=
Ca-Ski NYPVdlNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfuTWZKSzVyPUGyMlkxPDFizszN
TGBC1TKB NIPv[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KwOWlEPTB;MUKuPVEyPSEQvF2=
HCC1187 NXezR4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXjb2VsUUN3ME2xN{4yQTF{IN88US=>
SJSA-1 NGDY[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDETWM2OD1zMz6yN|I4KM7:TR?=
CTV-1 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF|LkO0OUDPxE1?
WM-115 M3PuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XvfGlEPTB;MUOuOlQ5OyEQvF2=
CHP-212 NUf2bGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\jTWM2OD1zMz65O|M6KM7:TR?=
SCC-15 M3Xt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF|Lkm3O|Uh|ryP
BPH-1 M4jPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF2LkG2OlQh|ryP
SW780 NVexTnFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD1zND61NFI2KM7:TR?=
NCI-H2291 M4HVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnZT|dKSzVyPUG0MlU5PzhizszN
JEG-3 NHvuUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrm[FJ4UUN3ME2xOE43OzJ4IN88US=>
CAL-120 NY\TVGEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PSOGlEPTB;MUSuO|AzPyEQvF2=
NCI-H23 NVu2VmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTDVVJoUUN3ME2xOE44QTl5IN88US=>
MS-1 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQcZZKSzVyPUG0Mlk3OTFizszN
PC-14 NHL4OFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzFTWM2OD1zND65OlU1KM7:TR?=
D-283MED Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF3LkCxNVEh|ryP
OE19 M{fnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXRbldxUUN3ME2xOU4yPTRzIN88US=>
CAS-1 NHv1c3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHPZ2FKSzVyPUG1MlQyQDRizszN
NCI-H727 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF3LkSyNlEh|ryP
SiHa M3i0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfPe|NKSzVyPUG1Mlc2QTRizszN
BFTC-905 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHuTWM2OD1zNT63Olk1KM7:TR?=
MDA-MB-453 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf5VodWUUN3ME2xOk4yPjR{IN88US=>
HuP-T3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL5TWM2OD1zNj62N|c{KM7:TR?=
SK-LU-1 NFPOe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnwNFJKSzVyPUG2MlY6PTZizszN
Detroit562 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfuXXR{UUN3ME2xOk44OzF6IN88US=>
HCC1569 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u3WGlEPTB;MU[uPFM{PyEQvF2=
SK-MES-1 NX;0XVhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF4Lki0NVkh|ryP
BB65-RCC NGnXNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\uTWM2OD1zNz6wOFc6KM7:TR?=
LOXIMVI MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnFTnRQUUN3ME2xO{4xPzB5IN88US=>
SW1783 NHXne3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF5LkGyPEDPxE1?
NH-12 NFnoV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi0em9KSzVyPUG3MlM{ODNizszN
UACC-257 M3v3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF5LkW1NVIh|ryP
KOSC-2 M1X0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfBVZFKSzVyPUG3MlY4PTdizszN
KG-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF5Lk[5N|ch|ryP
M059J M2XKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\HOZlKSzVyPUG3MlcxOyEQvF2=
MHH-NB-11 NVX6OZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF5Lkm2O|Mh|ryP
EW-1 NH[5cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF6LkGzPFIh|ryP
CAL-85-1 NH71c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHFTWM2OD1zOD6yN|U4KM7:TR?=
639-V NITxeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zTVWlEPTB;MUiuN|M2PCEQvF2=
C32 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF6LkS3Nlch|ryP
KM-H2 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtTWM2OD1zOD61NlMzKM7:TR?=
A253 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli5TWM2OD1zOD63Nlg3KM7:TR?=
NCI-N87 NF\kd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12yb2lEPTB;MUiuPVAxQCEQvF2=
8-MG-BA NHHjU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3UTWM2OD1zOT6wOlQ3KM7:TR?=
GI-ME-N NWjx[ZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrwTWM2OD1zOT6xOVQ3KM7:TR?=
8305C MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHXfVVKSzVyPUG5MlIzQDZizszN
TE-8 M1W4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrDTWM2OD1zOT6zNFI1KM7:TR?=
KYSE-270 M1zUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq2SYpPUUN3ME2yNE4xOjF5IN88US=>
HL-60 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;mOWlEPTB;MkCuNFk1OSEQvF2=
Mo-T M1XUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJyLkG2OlUh|ryP
NCI-H1355 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjKVmp4UUN3ME2yNE4{Ozd2IN88US=>
HT-1080 M361SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S2eWlEPTB;MkCuOVQ6PyEQvF2=
MIA-PaCa-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i4fmlEPTB;MkCuOlg5OyEQvF2=
NCI-H441 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rkVGlEPTB;MkCuO|M4QSEQvF2=
LCLC-97TM1 NX;kW4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPqS3JQUUN3ME2yNE45OTN2IN88US=>
HT-3 NIX6c2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7KTHJnUUN3ME2yNU42PjNzIN88US=>
22RV1 M4DPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXzdVZKSzVyPUKxMlU3QDVizszN
LK-2 NGrnZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJzLkW5OVMh|ryP
CW-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTIV4hKSzVyPUKxMlYxPjlizszN
KYSE-510 M2nqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrOS2RKSzVyPUKxMlYxQTVizszN
CGTH-W-1 M3v0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TwSmlEPTB;MkGuO|E3PiEQvF2=
NCI-H661 NYfEOXc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPPTWM2OD1{Mj6wN|Qh|ryP
KU-19-19 NF;I[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uyWGlEPTB;MkKuNVY6PyEQvF2=
NCI-H2122 NXqwcmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ{LkK0N|Ih|ryP
NCI-H526 NYnZT2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ{LkO4PVUh|ryP
NCI-H1650 NViyeVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrXVldUUUN3ME2yNk44PjRizszN
AM-38 NUXTU5lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jTe2lEPTB;MkKuPFY5QSEQvF2=
NCI-H2405 M4HBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHUOZQ6UUN3ME2yN{4zPTN|IN88US=>
M14 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HqVmlEPTB;MkOuOFA5QCEQvF2=
ES4 NGfycYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ|LkSyN|Ih|ryP
DJM-1 M2nlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HKfGlEPTB;MkOuOVI{PCEQvF2=
S-117 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHueG5KSzVyPUKzMlc3PTFizszN
MZ2-MEL NXnTRpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WzXGlEPTB;MkOuO|c2QSEQvF2=
SK-MEL-2 M3raRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfBTWM2OD1{Mz64NVM{KM7:TR?=
HCC1806 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ|Lki3NFkh|ryP
NMC-G1 NUnrWGhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDiVXFKSzVyPUK0MlIzOjZizszN
DK-MG M2\XNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ2LkK5OEDPxE1?
SK-N-FI MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DLOWlEPTB;MkSuN|MxOiEQvF2=
KINGS-1 NILxZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJ2LkS4O|Qh|ryP
HCC2998 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLlTWM2OD1{ND60PFg2KM7:TR?=
ALL-PO NVS0[FA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljqTWM2OD1{ND62NVkh|ryP
MPP-89 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzOUGs5UUN3ME2yOU4xPDV6IN88US=>
NCI-H2342 M{fnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXRTWM2OD1{NT6xPVU{KM7:TR?=
TE-1 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2xZnNKSzVyPUK1MlM2PjNizszN
RH-18 M1S0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ3LkW5NVgh|ryP
HT-1376 NH3UTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ3Lk[0OlUh|ryP
U-2-OS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID0dJhKSzVyPUK1MlY5QDhizszN
BT-549 M1HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnYW4xEUUN3ME2yOU46ODFzIN88US=>
NCI-H1755 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ3Lkm5OFUh|ryP
EW-13 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLNepZKSzVyPUK2MlAzPzRizszN
NB13 M4\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn76TWM2OD1{Nj6wPVQ6KM7:TR?=
NUGC-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHKTWM2OD1{Nj6yNVA{KM7:TR?=
GMS-10 NInnNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2yWo9UUUN3ME2yOk4zOzV|IN88US=>
CHP-134 NHvGfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ4LkO4Olch|ryP
SW962 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK0TWM2OD1{Nj61NFIyKM7:TR?=
SNU-449 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ5LkC4NFMh|ryP
HuP-T4 NFLaWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3RSlBKSzVyPUK3MlA5PzlizszN
SW948 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHUTWM2OD1{Nz6xN|Q1KM7:TR?=
NCI-H226 M4fN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfqVXcxUUN3ME2yO{41PTd6IN88US=>
SK-PN-DW NWHjU2M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnWcnNKSzVyPUK3MlYxOTJizszN
GI-1 NYfFOo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETRNVdKSzVyPUK3MlczOSEQvF2=
CAL-12T NEWxW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2PGlEPTB;MkiuNVEyOiEQvF2=
YAPC MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jNb2lEPTB;MkiuNlU3PCEQvF2=
SNU-C2B M3fjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ6LkK5OlQh|ryP
RCC10RGB NUS2RVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\BU4FKSzVyPUK4MlU1OTdizszN
ES7 NXvqfmNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP4TWM2OD1{OT6xOFY2KM7:TR?=
PANC-03-27 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ7LkS0OEDPxE1?
ES6 NVnW[nlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zKcWlEPTB;MkmuPFE2PyEQvF2=
HT-1197 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfrcpNKSzVyPUOwMlA2QThizszN
ZR-75-30 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNyLkKzPFMh|ryP
DB MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jhbGlEPTB;M{CuOFk1OiEQvF2=
OCI-AML2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn5OpFWUUN3ME2zNU4xPjlizszN
NCI-H2170 NI\RWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLaPYllUUN3ME2zNU45PTF4IN88US=>
IST-MES1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\wSmpoUUN3ME2zNk4zQDl5IN88US=>
769-P MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PmdmlEPTB;M{KuN|Y1OSEQvF2=
COR-L23 NFzDN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC5W3lsUUN3ME2zNk46ODd|IN88US=>
SW626 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN|LkG3O|Yh|ryP
LU-139 NGq2S|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4fGlEPTB;M{OuOlYxPSEQvF2=
HT-144 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN|Lki2N{DPxE1?
CaR-1 M{P1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES0SoZKSzVyPUOzMlk5OjJizszN
OE33 Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLZTWM2OD1|ND6yPFU2KM7:TR?=
COLO-800 NFHNeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3RTYNKSzVyPUO0MlM3PDdizszN
NB14 M4jLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTvTWM2OD1|ND60Olg1KM7:TR?=
KURAMOCHI MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3QTWM2OD1|Nj6xNVk5KM7:TR?=
SW48 M3WybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S5NGlEPTB;M{[uNlQ4PCEQvF2=
Daoy M4fWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33wd2lEPTB;M{[uOlU{QCEQvF2=
TGBC24TKB M3TvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DZWGlEPTB;M{[uOlch|ryP
DU-4475 NFq3d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\M[lJKSzVyPUO2MlkxOzNizszN
SW1417 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN6LkC1OVIh|ryP
EFO-21 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofnTWM2OD1|OD65N|Q6KM7:TR?=
MG-63 NEnFdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN7LkO0NlQh|ryP
LC-2-ad NGHlTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjHTpBiUUN3ME2zPU42PTF{IN88US=>
NOMO-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rDUmlEPTB;M{muPFI4PCEQvF2=
COLO-741 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRyLkGzNFQh|ryP
BxPC-3 M3;pWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3IZoFKSzVyPUSwMlU3QDZizszN
HSC-2 M4q3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HyfGlEPTB;NECuPVEyOyEQvF2=
UMC-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLwfohKSzVyPUSxMlI3OyEQvF2=
HCC1937 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXEeo1KSzVyPUSyMlc5PDNizszN
Calu-6 NV\wWFg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTR|LkKzPFIh|ryP
NCI-H1573 M4e2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvOmVKSzVyPUSzMlM1PzdizszN
SK-N-AS M2GwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HsT2lEPTB;NEOuOlAyQSEQvF2=
PSN1 NH3QdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnFTWM2OD12NT6yOVQ5KM7:TR?=
TE-11 NXTB[4d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPWTmZzUUN3ME20OU41QDR{IN88US=>
NCI-H1155 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDiOoNZUUN3ME20OU45QTZ5IN88US=>
KM12 NWjRW|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLwPGlKSzVyPUS1MlkxPzZizszN
RO82-W-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13tZWlEPTB;NE[uPVgzOiEQvF2=
SW1573 M2S5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i5[2lEPTB;NEeuN|c{PiEQvF2=
CAKI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPtUGZKSzVyPUS4MlI5PDVizszN
U-118-MG NILO[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHsWYxHUUN3ME20PE4{PzB{IN88US=>
KYSE-520 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR6LkSwNVYh|ryP
HT55 M3PN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\jXWlEPTB;NEmuNVQ4PCEQvF2=
ChaGo-K-1 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTR7LkS3PVMh|ryP
IA-LM M1v3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnaNpZMUUN3ME21OE43OzJ{IN88US=>
UACC-62 M2jRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SybmlEPTB;NUWuNVA1PiEQvF2=
MKN7 NWLHSWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPHeHdDUUN3ME21Ok4xOjh3IN88US=>
HPAF-II Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHntTWZKSzVyPUW2MlQxPzNizszN
NTERA-S-cl-D1 NYjlXGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHNTWM2OD13Nz63O|gh|ryP
FTC-133 NHruTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfaXXl7UUN3ME21PE4xQTZ7IN88US=>
MHH-ES-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTV6LkS4NVQh|ryP
JVM-2 NGjWbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHoTWM2OD13OD65OVA3KM7:TR?=
TCCSUP NFq2bWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTV7LkWyO|kh|ryP
COLO-824 NI\0b2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;nUmlEPTB;NkCuNFcyQSEQvF2=
647-V MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDWUIlKSzVyPU[wMlE{PDdizszN
HD-MY-Z M1fpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PEV2lEPTB;NkCuOVI6PCEQvF2=
LS-411N NHnFc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTZzLkO5NFMh|ryP
NCI-H596 M{PqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\2TIdKSzVyPU[yMlc1QTZizszN
C-33-A MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT6TWM2OD14ND6wPVU4KM7:TR?=
BHY MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHFb5pqUUN3ME22OE4yOjR3IN88US=>
KGN NEHIXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZ2LkW1NVQh|ryP
NCI-H1092 NIXy[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M161bGlEPTB;NkWuNFA6PSEQvF2=
MZ1-PC M{DKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{frPWlEPTB;NkWuOVY1QSEQvF2=
LB831-BLC MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfhNY5lUUN3ME22OU45PDhzIN88US=>
SW620 M1XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[3OmlEPTB;Nk[uNlA{QSEQvF2=
HuO-3N1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnDVIc1UUN3ME22PE4{OjN6IN88US=>
SK-HEP-1 M3TLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Qcm9KSzVyPU[5Mlk1QDZizszN
LCLC-103H MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTdyLk[3NFUh|ryP
KYSE-70 M{PzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjRVFJKSzVyPUewMlc5OzVizszN
Mewo MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zYPWlEPTB;N{GuOVA2KM7:TR?=
COLO-668 M3rBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTdzLki0OVEh|ryP
NCI-H522 M3\IRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M322eGlEPTB;N{KuN|QyOyEQvF2=
NCI-H1437 NWrqTIlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC1c5FKSzVyPUe0MlQxPDhizszN
U-266 M{jkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnnTolKUUN3ME23OU41PTF4IN88US=>
MC116 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TSXWlEPTB;N{WuOVcxQCEQvF2=
PANC-10-05 NF3IZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPjU4gzUUN3ME23O{41OjR|IN88US=>
KYSE-180 NIHMdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTd5LkW0OVQh|ryP
JAR MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHHTWM2OD15OT6wOVQ3KM7:TR?=
CAL-62 NFfMdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfieo1LUUN3ME24NE4xQTVizszN
A3-KAW Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWTWM2OD16MD6yNVU1KM7:TR?=
PANC-08-13 M1jFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRThzLkG3Olgh|ryP
HSC-3 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTh|LkOwO|Eh|ryP
HTC-C3 NYPre25XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO2T2ZKSzVyPUizMlQ4ODJizszN
KY821 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTh2LkC4PVIh|ryP
DoTc2-4510 NXzBenJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLMTWM2OD16ND6yNVg2KM7:TR?=
NCI-H1581 NVnNWlF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTh3LkS2OFEh|ryP
KARPAS-299 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTh4LkG5O|ch|ryP
IST-MEL1 NUXtU4lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTh4Lki4O|Ih|ryP
KP-N-YS NYqw[YN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfnRld4UUN3ME24PU46ODJ6IN88US=>
KYSE-410 NUTjUY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTlzLkSwOFIh|ryP
TE-10 M3n6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHGZW9KSzVyPUmxMlU3OTFizszN
SK-MEL-1 NXv0TGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXGTWM2OD17Mj65NVA3KM7:TR?=
COLO-792 NVf2bVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;BTJJRUUN3ME25OU4zPTZ2IN88US=>
SCH M4rUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTl4LkO4O|ch|ryP
NCI-H1792 M3jaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfPWVdKSzVyPUm2Mlg6QTJizszN
NCI-H2029 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\Te2ZKSzVyPUm2Mlk2PjZizszN
SW684 NHO0V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\6SGlEPTB;OUiuOlY2PCEQvF2=
NCI-H209 NIW1UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nKeWlEPTB;MUCwMlEzOSEQvF2=
HLE NYT2bXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFyNT6yPFIh|ryP
GOTO Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LWXWlEPTB;MUC3Mlc4PyEQvF2=
NCI-H1793 M2rxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFyOT6yPEDPxE1?
D-392MG MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[w[mlEPTB;MUG3MlM6QCEQvF2=
SW1990 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7wTWM2OD1zMkCuPVUyKM7:TR?=
ML-2 NETmU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f6eGlEPTB;MUKxMlY4PiEQvF2=
NCI-H2452 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLnRmV[UUN3ME2xNlIvOjFizszN
SK-MEL-30 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHQTWM2OD1zMkOuNlQ1KM7:TR?=
SN12C M1W5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV63bYRmUUN3ME2xNlQvOTd4IN88US=>
NCI-H1770 NHXEb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLBW4tKSzVyPUGyOU42OTRizszN
SF268 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3SGlEPTB;MUK2MlE2QCEQvF2=
BALL-1 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\XZ2lEPTB;MUK2MlI{KM7:TR?=
COLO-679 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfodZhwUUN3ME2xNlYvPzV|IN88US=>
A2780 NH3YO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTuZ5pKSzVyPUGyPE46QDhizszN
NCI-H1651 NH7qcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnjPHdKSzVyPUGzNU4zPDNizszN
NCI-H2087 NYrPd3FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnnfVNoUUN3ME2xN|EvPDh|IN88US=>
U-87-MG Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILOfnNKSzVyPUGzN{43ODRizszN
LB2518-MEL NYH5enliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF|NT65PVMh|ryP
HCT-116 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSydYFuUUN3ME2xN|cvOjF5IN88US=>
Ca9-22 NUfq[GZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF|OT64N|Mh|ryP
COR-L88 NXzoNXg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[5TXRKSzVyPUG0Nk4yPCEQvF2=
CP50-MEL-B MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nze2lEPTB;MUS0MlUxOSEQvF2=
OVCAR-8 NYjYZZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Q[VhnUUN3ME2xOFUvPjN4IN88US=>
SK-MEL-3 M2LW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF2Nz64O|gh|ryP
GT3TKB NEC4NlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fCVWlEPTB;MUS5MlkzQCEQvF2=
KYSE-450 NFnQ[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF3MT61N|kh|ryP
CAPAN-1 M4nNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULlbmtsUUN3ME2xOVMvODZ2IN88US=>
BEN NH3GdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjv[5BjUUN3ME2xOVMvQTJ6IN88US=>
NCI-H1304 M4fwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknXTWM2OD1zNUSuOlk1KM7:TR?=
KU812 M3z3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF3OD62O|Qh|ryP
Capan-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjx[HhKSzVyPUG2NE42PTNizszN
A673 M4f1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF4MT63NFUh|ryP
SAS NFzYV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMT2lEPTB;MU[yMlY4QCEQvF2=
NY MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF4NT6zNVQh|ryP
HCE-4 M1jBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjZcXJKSzVyPUG2Ok45PDVizszN
MDA-MB-231 M4[zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDGTWM2OD1zN{euOVA{KM7:TR?=
no-10 NI\mZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm5TWM2OD1zN{iuNVM1KM7:TR?=
MZ7-mel MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWyTWM2OD1zN{iuOFY4KM7:TR?=
NCI-H82 M3XXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrBb3ZKSzVyPUG4NE4yPjVizszN
CAL-72 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPHTWM2OD1zOEWuNFU1KM7:TR?=
NCI-SNU-5 NWfRc3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T0TWlEPTB;MUi2Mlg1KM7:TR?=
OVCAR-4 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITkbZVKSzVyPUG4PE4{OzNizszN
SCC-9 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULW[ZBTUUN3ME2xPVEh|ryP
KYSE-150 NFXafWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O4UmlEPTB;MUmxMlg5QCEQvF2=
HT-29 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJyMT6yNVIh|ryP
COLO-678 M1jSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPlTWM2OD1{MEGuOFUh|ryP
NCI-H650 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPOTWM2OD1{MEKuNVA{KM7:TR?=
HuCCT1 M2LRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuxTWM2OD1{MESuNlA5KM7:TR?=
SW1116 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJyNz6wO|ch|ryP
DBTRG-05MG MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW2TWM2OD1{MEeuPVA6KM7:TR?=
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D2eWlEPTB;MkC3Mlk1QCEQvF2=
RCM-1 NY\UTIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJzND63OlIh|ryP
COLO-320-HSR NF\5[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJzNj6xNlUh|ryP
KNS-42 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zsU2lEPTB;MkG2MlU4PCEQvF2=
C2BBe1 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ|MT65NFUh|ryP
CCRF-CEM NISxUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\HfmNSUUN3ME2yOFMvPzl3IN88US=>
SH-4 M1fMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe1TpVKSzVyPUK0Ok4xQSEQvF2=
LS-1034 NVGxTHlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W5Z2lEPTB;MkS2MlI3PiEQvF2=
NCI-H2347 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ2Nz63NVMh|ryP
RPMI-8866 NYXYS5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ2OT6yO{DPxE1?
GAK M1zue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ3Mz6wNFIh|ryP
NB6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnMNIYxUUN3ME2yO|AvOSEQvF2=
COLO-680N MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j2[mlEPTB;MkeyMlUzPyEQvF2=
RERF-LC-MS M4TPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ5Nj6wNFch|ryP
TGBC11TKB M4jQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPzOWpKSzVyPUK3PE4yPzhizszN
C8166 M4jDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKzTWM2OD1{N{iuOVA3KM7:TR?=
HDLM-2 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKxUVVKSzVyPUK5OE41ODlizszN
IGR-1 NVuzWG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5ZVlKSzVyPUK5OU43PTlizszN
FADU NEO5OWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXlTWM2OD1{OUeuOVEh|ryP
L-428 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL6bnNTUUN3ME2yPVcvPjF4IN88US=>
LU-65 M1jkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNyND6zNkDPxE1?
HEL NYj1fVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGz[2FKSzVyPUOwPU46QDNizszN
NCI-H810 NF\4N3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNzMD61O{DPxE1?
C3A Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\oTWM2OD1|MUGuPFAzKM7:TR?=
NCI-H630 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfkUFNuUUN3ME2zN|IvOjl2IN88US=>
KP-N-YN MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK1TWM2OD1|NEGuNVI{KM7:TR?=
MOLT-13 NXO4fJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fYRWlEPTB;M{SyMlMzPiEQvF2=
NCI-H1993 NVX3bXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW1XmZKSzVyPUO0Nk4{PjVizszN
BE-13 M4rKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN2ND6xOlch|ryP
IST-SL1 NEjvO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTN2Nz60NFEh|ryP
TE-9 NITpRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jmTGlEPTB;M{[zMlU5QSEQvF2=
LU-135 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPKeW5KSzVyPUO2O{4xOzVizszN
T84 NYXFTXBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLpd4J2UUN3ME2zO|QvPzF{IN88US=>
K-562 NXX0OYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPnbFlDUUN3ME2zPFMvOzZizszN
SBC-5 NULCNnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHFcop{UUN3ME2zPFYvQTh3IN88US=>
NB17 NWHqWG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN7Mj61PVYh|ryP
NCI-H2052 NITXXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3STWM2OD1|OUiuOFczKM7:TR?=
HCC38 NVfaU|h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn1TWM2OD12MEGuOVk{KM7:TR?=
NCI-H69 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7xeXBKSzVyPUS0NU4xQDNizszN

... Click to View More Cell Line Experimental Data

In vivo試験 MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
臨床試験 MK-2206 is currently under Phase II clinical trial for treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
特集 The first allosteric small molecule inhibitor of Akt to enter clinical development.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

細胞アッセイ: [2]

細胞系 A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
濃度 0, 0.3, 1 and 3 μM
処理時間 72 or 96 hours
方法 MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

動物実験: [2]

動物モデル SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
製剤 Formulated in 30% Captisol
投薬量 120 mg/kg
管理 Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MK-2206 2HCl SDF
分子量 480.39
化学式

C25H21N5O.2HCl

CAS No. 1032350-13-2
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

カスタマーレビュー (16)


Click to enlarge
Rating
Source Cancer Cell, 2013, 24, 766-76. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines T-ALL cells
Concentrations 10 uM
Incubation Time 5 h
Results western blot analysis with the AKT phosphorylationmotif antibody showed decreased AKT phosphorylated NR3C1in NR3C1 immunoprecipitates from CCRF-CEM T-ALL cellsupon AKT inhibition with MK2206

Click to enlarge
Rating
Source Cancer Cell, 2013, 24, 766-76. MK-2206 2HCl purchased from Selleck
Method flow cytometry
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results AKT1 inhibition of CCRF-CEM lymphoblasts with MK2206 effectivelyrestored glucocorticoid-induced apoptosis and reversed glucocorticoid resistance in vitro.

Click to enlarge
Rating
Source Cancer Cell, 2013, 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov, 2012, 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source Cancer Res, 2013, 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget, 2011, 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal, 2011, 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J, 2013, 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Gynecol Oncol, 2011, 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem, 2011, 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem, 2011, 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem, 2011, 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol, 2009, 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source Biochim Biophys Acta, 2012, 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

製品表彰状 (156)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related Akt 阻害剤

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • LY2584702

    LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • LY2090314

    LY2090314 は GSK-3α と GSK-3βのために、強力なGSK-3阻害剤で、IC50 がそれぞれ1.5 nM と 0.9 nMです。

  • AZD5363

    AZD5363は、有力なAkt阻害剤で、Akt1、Akt2とAkt3に作用すると、 IC50がそれぞれ 3 nM、 8 nM 、 8 nMです。

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068)は、5nM、18nMと8nMのIC50でAkt1、Akt2とAkt3を目標としている非常に選択的な汎Akt阻害剤です。

  • GSK690693

    GSK690693は、Akt1、Akt2とAkt3を目標としている汎Akt阻害剤で、IC50 がそれぞれ 2 nM、13 nM、9 nMです。

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401)は、4.7 nMのIC50による新しいAkt阻害剤です。

  • A-674563

    A-674563は、Akt1 抑制影響を示しまして、Ki が 11 nMです。

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

最近見られたアイテム

Tags: MK-2206 2HClを買う | MK-2206 2HCl供給者 | MK-2206 2HClを購入する | MK-2206 2HCl費用 | MK-2206 2HCl生産者 | オーダーMK-2206 2HCl | MK-2206 2HCl代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ